A 6-factor prognostic model for urothelial carcinoma patients receiving atezolizumab
Thoughts on HOPA 2018 and what’s to come: progress in the Oncology Pharmacy community
Looking towards the future: what is in store for the treatment of bladder cancer?
Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Highlights in the development of new therapies and novel drugs in treating melanoma